Laboratorios Richmond SACIF (RICH.BA) fair value

ACCE thesis

Laboratorios Richmond makes generic and specialty pharmaceuticals in Argentina, with a portfolio spanning oral solids, injectables and dermatology products sold through Argentine pharmacies and public tenders. Its moat is local: a long-established brand footprint and regulatory registrations that take years for a newcomer to replicate, which helps explain a 62.0% gross margin. The near-term problem is top-line contraction, with revenue down 13.6% and operating margin squeezed to 2.9%, so any recovery case depends on pricing and volume stabilizing in a volatile peso economy. At a trailing P/E of 8.4 and ROE of 13.2%, the stock screens cheap on earnings, but the 48/100 score and absence from any index reflect that the market is pricing the margin compression as persistent. This is worth a deeper look only if you can underwrite a clear path back toward volume growth and margin repair.